Key Takeaways
- TAN project nearing the finish line: EPC work hit 92% completion with an April 30, 2026 target; pre-commissioning has started and the first end product is expected by April.
- Complex fertilizers drove the top line, not the bottom: Segment revenue jumped 81% YoY on strong seasonal DAP and NPK volumes, but EBIT margins stayed thin at ~1.4% as higher input costs and the fixed-margin structure of traded DAP compressed profitability.
- The non-subsidy portfolio is scaling fast: CPC, speciality nutrients and seeds grew revenue 33% YoY at ~22.8% EBIT margins, while the biologicals portfolio saw volumes rise 31% and revenue nearly 58% over nine months.
- Capital return is off the table for now: Management explicitly stated that if its plans work out, there is nothing to offer shareholders in the next one or two years; all cash is earmarked for the TAN ramp, potential expansion, and overseas discussions.
- What to watch next quarter: The TAN plant's trial-run progress and initial production quality, any movement on the stalled G3 policy review, and whether the re-engaged overseas investment discussions translate into a concrete proposal.
TAN Project: Execution, Ramp & Market
- Construction status: EPC work reached 92% completion in Q3; the scheduled completion date is April 30, 2026, and pre-commissioning activities have begun for the WNA plant, with ANS and melt units to follow shortly thereafter.
- First product timeline: Management expects end product by April 2026, with the trial run now underway.
- FY'27 utilization confidence: Production ability is not expected to be an issue; the key variable is market absorption, and management expressed confidence in both its marketing team and the technology, stating there are no showstoppers for reaching very healthy utilization.
- Market growth trajectory: The TAN market is growing at roughly 5-6% CAGR, driven by infrastructure, data centers, copper, cement, and coal-based power demand; private sector involvement in metals mining is expected to open up significantly in the next 3-4 years.
- Supply-side caution: The market will shortly become long as Chambal's capacity and others (e.g., Gopalpur at Deepak) come online in the next one to two years.
- Strategic hedge: Vertical integration into specific products for the mining sector is being evaluated, which would insulate the company from commodity-grade TAN cycles.
- Expansion scope: Both horizontal (more of the same product) and vertical (forward in the value chain) possibilities are being actively explored; a specific proposal with cost, return, and product mix will be announced when it goes to the Board.
- Coal-gasification competition: Coal India and BHEL are talking about a four-year timeline for their coal-based technology; management believes there is enough space for all players.
Baijal: "I am pretty confident that the trajectory is going to go higher."
Complex Fertilizers: Volume Surge, Margin Squeeze
- Q3 revenue breakout: Complex fertilizer segment revenue rose 81% YoY to ~₹1,850 crores, with sales volume climbing to 2.94 lakh metric tons from 2.13 lakh metric tons, reflecting strong seasonal demand for DAP, TSP and NPK grades.
- Nine-month trend: Segment revenue reached ~₹6,702 crores, up 180% YoY, on volumes of 11.7 lakh metric tons; however, EBIT margins moderated to ~4.4% from 6.87% a year ago as input cost pressures bit.
- DAP margin mechanics: Traded DAP is a fixed-margin business where the government allows 4% of MRP (~₹1,026 per ton); procurement at sharply higher prices (up to $850) means that ₹1,000 on a ₹60,000 product is a very small absolute margin, dragging segment profitability down.
- Input cost headwinds: Phosphoric acid and sulfuric acid prices have increased significantly; sulfur is very high and not expected to come down soon, with knock-on effects on phosphoric acid costs, making DAP production economics challenging. Ammonia also remains at slightly elevated levels.
- NPK margin pressure: The economics do not work out at all for NPKs currently; even grade 20-20-0-13 is under margin pressure due to sulfur prices, and unlike DAP, NPKs have no policy protection.
- Substitution risk: Farmers will tolerate a price gap between DAP and NPK only up to a point; last year the substitute was not available, which helped NPK volumes, but that dynamic may shift if pricing diverges further.
- DAP producer economics: For domestic producers, the subsidy formula is derived from actual import material prices over the last six months; DAP prices were at $650-670 in January but have climbed sharply to $720-730, and the starting stock position this time is more favorable.
Non-Subsidy Portfolio: Biologicals, CPC & Seeds
- CPC and speciality nutrients: Segment revenue grew 33% YoY to ~₹340 crores in Q3, with EBIT margins holding at a healthy ~22.8%, driven by portfolio expansion and improved market penetration.
- Biologicals acceleration: Volumes increased 31% and revenue grew nearly 58% YoY over the nine-month period; the flagship Uttam Pranaam product saw volumes and revenue rise almost 250% YoY.
- TERI partnership: A joint research agreement with TERI is now operational with a dedicated lab commissioned; IP is jointly owned with Chambal holding exclusive global commercial rights; a pipeline of 8-9 products is in development across bionematicides, fungicides and other varieties, with launches expected from FY27-28 onwards.
- Product launch cadence: Five new products were introduced in Q3 across biopesticides, bio-fungicides and insecticides; 12 new CPC products and one new speciality nutrient product are lined up for FY27.
- Seed business entry: Research-variety wheat was launched this year with encouraging early results; mustard, pearl millet and wheat were tested in small quantities; inquiries for potential stakes have been received but no structure is decided.
- CPC manufacturing model: Chambal is exploring a TERI-like model where third parties develop and manufacture white-label generic combinations; asset acquisition on the CPC side is not on the table currently.
- International potential: One or two companies are evaluating Chambal's product performance; after field trials, products could be taken abroad; TERI-developed products may also enter export markets based on efficacy.
- Nutrien agreement: Nutrien Worldwide will supply carbon-related products starting next year.
Urea: Steady State, Turnaround Cycle Extension
- Stable performance: Urea segment revenue was broadly flat YoY at ₹3,708 crores, with EBIT margins stable at ~17.28%; sales volumes were largely flat at 9.83 lakh metric tons versus 9.88 lakh metric tons.
- Operational incident: Gadepan-I experienced a minor stripper leak that lasted three days; otherwise, the quarter was steady in terms of production.
- Capacity constraint: Urea volumes remain static as all three plants run beyond 100% capacity; the plants are currently on a two-year turnaround cycle.
- Turnaround cycle extension: Management is working to move all three plants from a two-year to a three-year turnaround cycle; success would unlock currently unexploited capacity.
- Gadepan-II shutdown: A maintenance shutdown began effective 20th February and is expected to last 30-35 days.
Policy, Subsidy & Regulatory Landscape
- Subsidy flows on track: Q3 subsidy receipts were ₹3,880 crores versus ₹3,349 crores last year; nine-month receipts of ~₹10,228 crores are broadly in line with ₹10,353 crores last year.
- NBS policy expectation: Management expects more or less a continuation from the past; the government is unlikely to open up the DAP segment, while other NPK grades remain open in terms of pricing; the government is seized of working capital management problems and is expected to come forward with a resolution.
- G3 policy benefits: stalled and uncertain: Gadepan-III's tenure under the G3 policy has expired, but the government has not started the exercise to determine how profit or cost calculations will be treated going forward; management has raised the issue at least twice in the last quarter with no progress.
- No precedent to lean on: Management declined to hazard a guess on the outcome, noting that the numbers could vary from its own estimates both positively and negatively, and that the treatment of net fixed assets and return on net worth remains open to question.
Baijal: "Given that Chambal-III, that is Gadepan-III, has finished its tenure, in what way they will treat these numbers is something open to question. We are not hazarding a guess as to what they will do. The numbers could vary from our estimate, both positively and negatively."
Capital Allocation & Strategic Optionality
- Near-term shareholder returns paused: Management was explicit that if its plans work out, there is nothing to offer shareholders in the next one or two years in terms of increased cash returns; beyond that, the position will be reviewed.
- Overseas investment discussions: Active discussions are underway with significant and positive re-engagement after a period of breaking off; management declined to provide specifics on where it will lead or on timing.
- IMACID JV expansion: P2O5 production capacity is being increased from 5 lakh metric tons to 7 lakh metric tons, expected by December 2026; sulfuric acid capacity is also being expanded, with completion expected in FY27.
- Phosphatic fertilizer capacity: Demand for phosphatic fertilizers continues to grow; Chambal is exploring and evaluating capacity options both in India and abroad.
- Seed business stake: Inquiries have been received for potential stakes, but management does not know what structure will work, citing valuation uncertainty.
Baijal: "I can only report that we are in active discussions, and we continue to have active discussions. But as I said last time, sometimes you break off and then engage. So, this is a time when I am talking to you, we have had a significant re-engagement, and, where it will lead to, we will have to wait for some time. But I think there has been a re-engagement and a positive re-engagement."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| TAN project completion | EPC work at 92%; end product expected | April 30, 2026 |
| TAN trial run and first output | Pre-commissioning started; end product from WNA, ANS and Melt | April 2026 |
| Gadepan-II maintenance shutdown | 30-35 day shutdown | Began 20th February 2026 |
| IMACID P2O5 capacity expansion | Increase from 5 lakh MT to 7 lakh MT | December 2026 |
| IMACID sulfuric acid capacity expansion | Capacity increase | FY27 |
| New CPC and speciality nutrient launches | 12 new CPC products, 1 new speciality nutrient product | FY27 |
| TERI-developed product launches | Pipeline of 8-9 products across bionematicides, fungicides | FY27-28 onwards |
| Urea plant turnaround cycle extension | Move from two-year to three-year cycle for all three plants | No date (effort underway) |
| TAN horizontal/vertical expansion proposal | Board proposal with cost, return and product mix | No date (active exploration) |
| Overseas investment outcome | Active discussions with positive re-engagement | No date (waiting for progress) |
| Shareholder cash returns | Nothing to offer if plans work out | Next 1-2 years |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue from operations | ₹5,898 cr, up 20% YoY |
| EBITDA | ₹821 cr, up 6% YoY; includes ₹31 cr hit from labour codes |
| EBITDA margin | 13.92% |
| Profit after tax | ₹565 cr, up 12% YoY |
| PAT margin | 9.57% |
| Revenue from operations (9M FY26) | ₹18,009 cr, up 27% YoY |
| EBITDA (9M FY26) | ₹2,424 cr, up 4% YoY; EBITDA margin 13.46% |
| Profit after tax (9M FY26) | ₹1,804 cr, up 16% YoY; PAT margin 10.02% |
| Subsidy received in the quarter | ₹3,880 cr, vs ₹3,349 cr in Q3 last year |
| Total receivables as of Dec 31, 2025 | ₹2,346 cr, comprising market debtors ₹367 cr and subsidy receivables ₹1,979 cr |
| Urea sales volume | 9.83 lakh MT, broadly flat YoY (9.88 lakh MT) |
| Urea EBIT margin | ~17.28%, broadly stable YoY |
| Complex fertilizer revenue | ~₹1,850 cr, up 81% YoY |
| Complex fertilizer sales volume | 2.94 lakh MT, vs 2.13 lakh MT last year |
| Complex fertilizer EBIT margin | ~1.4% |
| CPC, Speciality Nutrients and Seed segment revenue | ~₹340 cr, up 33% YoY |
| CPC, Speciality Nutrients and Seed segment EBIT margin | ~22.8% |
| Biologicals revenue growth (9M FY26) | ~58% YoY |
| Biologicals volume growth (9M FY26) | 31% YoY |
| Uttam Pranaam volume and revenue growth (9M FY26) | ~250% YoY |
| Biologicals market share | ~6% |
| Gas cost | $14.6 per MMBtu, NCV basis |
| Total urea production | 9.04 lakh MT (G-I: 2.84, G-II: 2.69, G-III: 3.51) |
| TAN project EPC completion | 92% as of Q3; completion date April 30, 2026 |
| TAN project expenditure incurred | ₹1,184 cr out of total estimated ₹1,645 cr |
| Net cash and liquid investments | ~₹800 cr |
| Traded business EBITDA per ton | ~₹900 (per an analyst's math) |
| DAP inventory end of January 2026 | ~0.25 crore tons, vs ~0.13 crore tons last year |
| Expected DAP opening inventory April 1, 2026 | 0.28 crore tons |